ECSP23016038A - NEW COMPOSITION OF MODIFIED RELEASE ORAL CONTRACEPTIVE - Google Patents
NEW COMPOSITION OF MODIFIED RELEASE ORAL CONTRACEPTIVEInfo
- Publication number
- ECSP23016038A ECSP23016038A ECSENADI202316038A ECDI202316038A ECSP23016038A EC SP23016038 A ECSP23016038 A EC SP23016038A EC SENADI202316038 A ECSENADI202316038 A EC SENADI202316038A EC DI202316038 A ECDI202316038 A EC DI202316038A EC SP23016038 A ECSP23016038 A EC SP23016038A
- Authority
- EC
- Ecuador
- Prior art keywords
- release oral
- modified release
- new composition
- oral contraceptive
- 17alpha
- Prior art date
Links
- 229940127234 oral contraceptive Drugs 0.000 title 1
- 239000003539 oral contraceptive agent Substances 0.000 title 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
La invención se refiere a una nueva forma farmacéutica oral de liberación modificada que comprende 17alfa-cianometil-17-ß-hidroxiestra-4,9-dien-3-ona (dienogest) y 17alfa-etinilestradiol (etinilestradiol), a su método de producción y a sus usos médicos y no médicos, en particular a su uso en anticoncepción.The invention refers to a new modified-release oral pharmaceutical form comprising 17alpha-cyanomethyl-17-ß-hydroxyestra-4,9-dien-3-one (dienogest) and 17alpha-ethinylestradiol (ethinylestradiol), its production method and its medical and non-medical uses, in particular its use in contraception.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382753.0A EP3954364A1 (en) | 2020-08-14 | 2020-08-14 | New modified release oral contraceptive composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23016038A true ECSP23016038A (en) | 2023-04-28 |
Family
ID=72145348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202316038A ECSP23016038A (en) | 2020-08-14 | 2023-03-06 | NEW COMPOSITION OF MODIFIED RELEASE ORAL CONTRACEPTIVE |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240041775A1 (en) |
| EP (2) | EP3954364A1 (en) |
| JP (1) | JP2023538030A (en) |
| KR (1) | KR20230067614A (en) |
| CN (1) | CN116322701A (en) |
| AU (1) | AU2021325372A1 (en) |
| BR (1) | BR112023002654A2 (en) |
| CA (1) | CA3191326A1 (en) |
| CL (1) | CL2023000450A1 (en) |
| CO (1) | CO2023002874A2 (en) |
| CR (1) | CR20230127A (en) |
| DO (1) | DOP2023000029A (en) |
| EC (1) | ECSP23016038A (en) |
| IL (1) | IL300578A (en) |
| MX (1) | MX2023001868A (en) |
| PE (1) | PE20231378A1 (en) |
| UY (1) | UY39379A (en) |
| WO (1) | WO2022034209A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2594939A1 (en) | 2005-02-15 | 2006-08-24 | Bayer Schering Pharma Aktiengesellschaft | Solid peroral contraceptive drug |
| TW201008569A (en) * | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
-
2020
- 2020-08-14 EP EP20382753.0A patent/EP3954364A1/en not_active Withdrawn
-
2021
- 2021-08-13 WO PCT/EP2021/072584 patent/WO2022034209A1/en active Application Filing
- 2021-08-13 MX MX2023001868A patent/MX2023001868A/en unknown
- 2021-08-13 AU AU2021325372A patent/AU2021325372A1/en active Pending
- 2021-08-13 UY UY0001039379A patent/UY39379A/en unknown
- 2021-08-13 CN CN202180070759.5A patent/CN116322701A/en active Pending
- 2021-08-13 US US18/021,165 patent/US20240041775A1/en active Pending
- 2021-08-13 EP EP21762678.7A patent/EP4196098A1/en active Pending
- 2021-08-13 CR CR20230127A patent/CR20230127A/en unknown
- 2021-08-13 BR BR112023002654A patent/BR112023002654A2/en unknown
- 2021-08-13 IL IL300578A patent/IL300578A/en unknown
- 2021-08-13 CA CA3191326A patent/CA3191326A1/en active Pending
- 2021-08-13 JP JP2023511588A patent/JP2023538030A/en active Pending
- 2021-08-13 PE PE2023000270A patent/PE20231378A1/en unknown
- 2021-08-13 KR KR1020237008915A patent/KR20230067614A/en unknown
-
2023
- 2023-02-10 DO DO2023000029A patent/DOP2023000029A/en unknown
- 2023-02-14 CL CL2023000450A patent/CL2023000450A1/en unknown
- 2023-03-06 EC ECSENADI202316038A patent/ECSP23016038A/en unknown
- 2023-03-09 CO CONC2023/0002874A patent/CO2023002874A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021325372A1 (en) | 2023-03-30 |
| MX2023001868A (en) | 2023-05-09 |
| US20240041775A1 (en) | 2024-02-08 |
| IL300578A (en) | 2023-04-01 |
| WO2022034209A1 (en) | 2022-02-17 |
| EP4196098A1 (en) | 2023-06-21 |
| UY39379A (en) | 2022-01-31 |
| PE20231378A1 (en) | 2023-09-07 |
| CN116322701A (en) | 2023-06-23 |
| BR112023002654A2 (en) | 2023-04-04 |
| EP3954364A1 (en) | 2022-02-16 |
| CA3191326A1 (en) | 2022-02-17 |
| DOP2023000029A (en) | 2023-07-09 |
| CO2023002874A2 (en) | 2023-04-05 |
| CL2023000450A1 (en) | 2023-10-20 |
| CR20230127A (en) | 2023-06-23 |
| KR20230067614A (en) | 2023-05-16 |
| JP2023538030A (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120860A1 (en) | PHARMACEUTICAL COMBINATION INCLUDING LEVONORGESTREL IN COMBINATION WITH PYROXICAM, INDOMETACIN OR DICLOFENACO | |
| CO4290424A1 (en) | PIRAZOLOPIRIDINES, PYRROLOPYRIDIDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR ITS ADMINISTRATION AS AN ANTAGONIST OF THE CORTICO-TROPINE RELEASE FACTOR | |
| ECSP088390A (en) | METHOD FOR PREVENTIVE HORMONAL ANTI-CONCEPTION UNDER DEMAND | |
| AR057060A1 (en) | TANAPROGET COMPOSITIONS CONTAINING ETHYL ESTRADIOL | |
| CY1118996T1 (en) | USING OSTETROL AS AN EMERGENCY EMERGENCY | |
| AR080912A1 (en) | ORAL SOLID DOSAGE FORMS WITH VERY LOW DOSE FOR HRT | |
| ECSP088123A (en) | ORAL CONTRACEPTION WITH TRIMEGESTONE | |
| CL2008001756A1 (en) | Interference RNA Agent (IARN); pharmaceutical composition comprising it; and its use to treat pathological processes mediated at least in part by the expression of the epithelial sodium channel alpha (alpha-enac) | |
| ECSP066999A (en) | PHARMACEUTICAL PACKAGING FOR FLEXIBLE EXTENDED REGIME HORMONAL ANTI-CONCEPTION | |
| DE502008002148D1 (en) | MEDICINE COMPREHENSIVE AT LEAST ONE GESTURED | |
| PE20040068A1 (en) | ETONOGESTREL DECANOATE, UNDECANOATE AND DODECANOATE | |
| PE20211588A1 (en) | COMPOUNDS AND THEIR USES TO RELIEVE SYMPTOMS ASSOCIATED WITH MENOPAUSE | |
| CO2023002874A2 (en) | New composition of modified release oral contraceptive | |
| CO7111317A2 (en) | Method for the treatment of gynecological diseases | |
| CL2019000174A1 (en) | Vaginal composition comprising a combination of estrogen and vitamin d. | |
| AR120976A1 (en) | SYSTEM TO PROVIDE BIRTH CONTROL | |
| BRPI0511864A (en) | use of a combination of ethinyl estradiol and chormadinone acetate for the preparation of a medicament | |
| EP3881843A4 (en) | Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease | |
| CO2022014548A2 (en) | Solid oral dosage form comprising pomalidomide | |
| PE20090805A1 (en) | COMBINATION OF DROSPIRENONE AND 17ß-ESTRADIOL AS AN ORAL CONTRACEPTIVE | |
| UY29861A1 (en) | USE OF ESTRADIOL VALERATE IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY OF THE UNITED DYSFUNCTIONAL UTERINE HEMORRAGY WITH AN ORAL ANTICONCEPTION | |
| UY29860A1 (en) | PROCEDURE FOR THE PRODUCTION OF A SINGLE PHASE PHARMACEUTICAL PREPARATION FOR ORAL THERAPY OF DYSFUNCTIONAL UTERINE HEMORRAGY | |
| AR070023A1 (en) | USE OF GESTAGENS IN COMBINATION WITH (6S) -5-METHYL-TETRAHYDROPHOLATE FOR THERAPY OF ENDOMETRIOSIS WITH SIMULTANEOUS REDUCTION OF THERAPEUTIC COLLATERAL EFFECTS AND REDUCTION OF THE RISK OF CONGENITAL MALFORMATIONS AT THE BEGINNING OF BEGIN | |
| ECSP23031196A (en) | PHARMACEUTICAL COMPOSITION SUITABLE FOR VAGINAL ADMINISTRATION IN THE FORM OF OVUMES AND USE THEREOF | |
| BR112022011992A2 (en) | COMPOSITIONS FOR ORAL HYGIENE |